Generic Injectable Market (By Product Type: Chemotherapy agents, Small molecule antibiotics, Vaccines, Peptide antibiotics, Blood factors, Peptide hormone, Insulin, Cytokines, Immunoglobin, Monoclonal Antibodies; By Molecular Type: Small Molecule, Large Molecule; By Application; By Administration; By Distribution Channel) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2034
The global generic injectable market size was USD 102.60 billion in 2023, calculated at USD 116.96 billion in 2024, and is expected to reach around USD 433.61 billion by 2034. The market is expanding at a solid CAGR of 14% over the forecast period 2024 to 2034.
Access our Healthcare Data Intelligence Tool with 10000+ Database, Visit: Towards Healthcare
The U.S. generic injectable market size was estimated at USD 33.10 billion in 2023 and is predicted to be worth around USD 142.89 billion by 2034, at a CAGR of 14.2% from 2024 to 2034.
Segmentation of generic injectables based on geography sector North America to be the leading region with highest market growth of the generic injectables with increased development of the generic injectables with increased research and development from the key market players for introducing the generic injectables with increased demand from the health care center due to shortage of the injectable with increased chronic infectious diseases among the population with increased hospitalization rate of the patients.
Asia pacific region also helps to boost the market growth with increased demand from the health care centre for generic injectables with increased chronic diseases increasing due to rising population. Other regions such as Europe, Latin America, Middle East and Africa contributes to increase the market of generic injectables to a larger extend.
Market Overview
The generic injectable drug is the compound having therapeutic characteristics with increased efficiency, potent. Which focus to kill the disease or the chronic infection. The generic drug basically is the chemical substance with increased developments and continuous research have increased the availability of the generic drugs in the market with fast approval of the drug. There are two categorisation involves generic drug and branded drug. Generic drug is basically same with the branded drug with same active pharmaceutical ingredient, with equal safety, quality, strength, efficiency, output of the drug, route of administration is same of both generic and branded drugs.
Therefore, increased focus on producing and manufacturing the generic drug with increased efficiency and decreased adverse drug reactions of the generic drugs. Increased chronic diseases among the population with increased medications enhanced the market of generic injectable drugs. Changing lifestyle of the people with increased diseases strives the market growth. Increased various new launch of the generic drugs as that of branded drugs with expiry of patents which reduced the new launch of the drug. Which helps to boost the market of generic injectable.
Impact of covid-19 viral disease, wide spread of virus across the regions with increase patient hospitalisation rate with increased demand for the drugs which fuels the market growth of generic drugs with cost effective benefit from the generic drugs.
The advanced developed drugs with increased efficacy of the drugs with increased research and development for producing the new generic drugs with fast approval of the new drug for increasing chronic diseases across the regions with increased adoption of the new lifestyle and habitual has increased the number of diseases, different dietary intake which is the major factor of increasing the disease. Increasing population with increasing infectious disease which led to short of generic injectable drugs which increased production of the generic drugs enhanced the market to grow at a larger extend.
Generic injectable drugs are less expensive than the branded drugs with increased cost of the drugs. Generic drug is highly affordable for the customers with very low cost of the drugs. Which led to increased demands from the health care sector for the generic injectable with increased efficacy and therapeutic index. Expansion of the generic injectable with various developments in routes of administration with increased research and developments in generic drugs drives the market of generic injectable with increased demand. Brand injectable comes with the expiry of the patent therefore reduced the number of introductions of the new drugs. Which led to increase research, production and manufacturing of the generic injectables fuels the market growth.
Research and development steps are less than branded drugs with fast approval and production of the generic injectable with increased demand from the health care sector expanded the market growth. The key market players involved in introducing the new generic drugs with increased investment for research and developed helps to boost the market growth at a larger extent during the forecast period. Increased government interest in developing the generic injectables due to decreased launch of the generic drugs and low cost of the generic with increased investment have rise the market to grow high.
Report Coverage | Details |
Market Size in 2023 | USD 101.97 Billion |
Market Size in 2024 | USD 101.97 Billion |
Market Size by 2034 | USD 101.97 Billion |
Growth Rate from 2024 to 2034 | CAGR of 13.8% |
Base Year | 2023 |
Forecast Period | 2024 to 2034 |
Segments Covered | Product Type, Molecular Type, Application, Administration, and Distribution Channel |
Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Rising prevalence of chronic infectious diseases
Increased population in the regions with increased infectious diseases among the people which led to increased number of patients for hospitalization with increased demand for the generic injectable drugs. Branded drugs come with patent expiry with decreased launch of the new generic injectable drug therefore expanded the demand for the generic injectables with similar efficacy, quality, strength, potent, safety. Which boosts the generic injectable market to a greater extend.
Cost effectivity of the generic injectables
Key Market Opportunities
Monoclonal antibodies to hold the highest market share with increased revenue during the forecast period of generic injectables.
Molecule Type Insight
Increased research and development in large molecules for developing the generic injectables with increased opportunity and increased share in the market. Which helps to increase the market of generic injectables. However, the small molecule segment is poised to grow at a higher CAGR during the forecast period 2024 to 2034.
Increased growth of the diabetes disease with increased life style and dietary supplements with high rate of patients among the population due to the previous family or increased obesity. Which led to increase of the diabetes with increased demand for the generic injectables. Oncology is also rising from the year 2023 with increased chemotherapies and generic injectables with high demand for the medication from the health care centre. However, the diabetes segment is growing at the strongest CAGR from 2024 to 2034.
Distribution Channel Insight
Segmentation of generic injectables based on distribution channel involves Hospital pharmacy, retail pharmacy, drug stores and online pharmacy. Due to increased chronic infectious diseases with enlargement of the hospitals with their own hospital pharmacy increase growth of the hospital across the regions. Hospital pharmacy to hold the largest market.
Segments Covered in the Report
By Product Type
By Molecular Type
By Application
By Administration
By Distribution Channel
By Geography
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Generic Injectable Market
5.1. COVID-19 Landscape: Generic Injectable Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Generic Injectable Market, By Product Type
8.1. Generic Injectable Market, by Product Type, 2024-2034
8.1.1. Chemotherapy agents
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Small molecule antibiotics
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. Vaccines
8.1.3.1. Market Revenue and Forecast (2021-2034)
8.1.4. Peptide antibiotics
8.1.4.1. Market Revenue and Forecast (2021-2034)
8.1.5. Blood factors
8.1.5.1. Market Revenue and Forecast (2021-2034)
8.1.6. Peptide hormone
8.1.6.1. Market Revenue and Forecast (2021-2034)
8.1.7. Insulin
8.1.7.1. Market Revenue and Forecast (2021-2034)
8.1.8. Cytokines
8.1.8.1. Market Revenue and Forecast (2021-2034)
8.1.9. Immunoglobin
8.1.9.1. Market Revenue and Forecast (2021-2034)
8.1.10. Monoclonal Antibodies
8.1.10.1. Market Revenue and Forecast (2021-2034)
Chapter 9. Global Generic Injectable Market, By Molecular Type
9.1. Generic Injectable Market, by Molecular Type, 2024-2034
9.1.1. Small Molecule
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Large Molecule
9.1.2.1. Market Revenue and Forecast (2021-2034)
Chapter 10. Global Generic Injectable Market, By Application
10.1. Generic Injectable Market, by Application, 2024-2034
10.1.1. Oncology
10.1.1.1. Market Revenue and Forecast (2021-2034)
10.1.2. Diabetes
10.1.2.1. Market Revenue and Forecast (2021-2034)
10.1.3. Infectious Diseases
10.1.3.1. Market Revenue and Forecast (2021-2034)
10.1.4. Blood Disorders
10.1.4.1. Market Revenue and Forecast (2021-2034)
10.1.5. Musculoskeletal Disorders
10.1.5.1. Market Revenue and Forecast (2021-2034)
10.1.6. Hormonal Disorders
10.1.6.1. Market Revenue and Forecast (2021-2034)
10.1.7. Pain Management
10.1.7.1. Market Revenue and Forecast (2021-2034)
10.1.8. CNS Diseases
10.1.8.1. Market Revenue and Forecast (2021-2034)
10.1.9. Cardiovascular Diseases
10.1.9.1. Market Revenue and Forecast (2021-2034)
Chapter 11. Global Generic Injectable Market, By Administration
11.1. Generic Injectable Market, by Administration, 2024-2034
11.1.1. Intravenous (IV)
11.1.1.1. Market Revenue and Forecast (2021-2034)
11.1.2. Intramuscular (IM)
11.1.2.1. Market Revenue and Forecast (2021-2034)
11.1.3. Intramuscular (IM)
11.1.3.1. Market Revenue and Forecast (2021-2034)
Chapter 12. Global Generic Injectable Market, By Distribution Channel
12.1. Generic Injectable Market, by Distribution Channel, 2024-2034
12.1.1. Hospital pharmacy
12.1.1.1. Market Revenue and Forecast (2021-2034)
12.1.2. Hospital pharmacy
12.1.2.1. Market Revenue and Forecast (2021-2034)
12.1.3. Drug stores
12.1.3.1. Market Revenue and Forecast (2021-2034)
12.1.4. Online pharmacy
12.1.4.1. Market Revenue and Forecast (2021-2034)
Chapter 13. Global Generic Injectable Market, Regional Estimates and Trend Forecast
13.1. North America
13.1.1. Market Revenue and Forecast, by Product Type (2021-2034)
13.1.2. Market Revenue and Forecast, by Molecular Type (2021-2034)
13.1.3. Market Revenue and Forecast, by Application (2021-2034)
13.1.4. Market Revenue and Forecast, by Administration (2021-2034)
13.1.5. Market Revenue and Forecast, by Distribution Channel (2021-2034)
13.1.6. U.S.
13.1.6.1. Market Revenue and Forecast, by Product Type (2021-2034)
13.1.6.2. Market Revenue and Forecast, by Molecular Type (2021-2034)
13.1.6.3. Market Revenue and Forecast, by Application (2021-2034)
13.1.6.4. Market Revenue and Forecast, by Administration (2021-2034)
13.1.6.5. Market Revenue and Forecast, by Distribution Channel (2021-2034)
13.1.7. Rest of North America
13.1.7.1. Market Revenue and Forecast, by Product Type (2021-2034)
13.1.7.2. Market Revenue and Forecast, by Molecular Type (2021-2034)
13.1.7.3. Market Revenue and Forecast, by Application (2021-2034)
13.1.7.4. Market Revenue and Forecast, by Administration (2021-2034)
13.1.7.5. Market Revenue and Forecast, by Distribution Channel (2021-2034)
13.2. Europe
13.2.1. Market Revenue and Forecast, by Product Type (2021-2034)
13.2.2. Market Revenue and Forecast, by Molecular Type (2021-2034)
13.2.3. Market Revenue and Forecast, by Application (2021-2034)
13.2.4. Market Revenue and Forecast, by Administration (2021-2034)
13.2.5. Market Revenue and Forecast, by Distribution Channel (2021-2034)
13.2.6. UK
13.2.6.1. Market Revenue and Forecast, by Product Type (2021-2034)
13.2.6.2. Market Revenue and Forecast, by Molecular Type (2021-2034)
13.2.6.3. Market Revenue and Forecast, by Application (2021-2034)
13.2.7. Market Revenue and Forecast, by Administration (2021-2034)
13.2.8. Market Revenue and Forecast, by Distribution Channel (2021-2034)
13.2.9. Germany
13.2.9.1. Market Revenue and Forecast, by Product Type (2021-2034)
13.2.9.2. Market Revenue and Forecast, by Molecular Type (2021-2034)
13.2.9.3. Market Revenue and Forecast, by Application (2021-2034)
13.2.10. Market Revenue and Forecast, by Administration (2021-2034)
13.2.11. Market Revenue and Forecast, by Distribution Channel (2021-2034)
13.2.12. France
13.2.12.1. Market Revenue and Forecast, by Product Type (2021-2034)
13.2.12.2. Market Revenue and Forecast, by Molecular Type (2021-2034)
13.2.12.3. Market Revenue and Forecast, by Application (2021-2034)
13.2.12.4. Market Revenue and Forecast, by Administration (2021-2034)
13.2.13. Market Revenue and Forecast, by Distribution Channel (2021-2034)
13.2.14. Rest of Europe
13.2.14.1. Market Revenue and Forecast, by Product Type (2021-2034)
13.2.14.2. Market Revenue and Forecast, by Molecular Type (2021-2034)
13.2.14.3. Market Revenue and Forecast, by Application (2021-2034)
13.2.14.4. Market Revenue and Forecast, by Administration (2021-2034)
13.2.15. Market Revenue and Forecast, by Distribution Channel (2021-2034)
13.3. APAC
13.3.1. Market Revenue and Forecast, by Product Type (2021-2034)
13.3.2. Market Revenue and Forecast, by Molecular Type (2021-2034)
13.3.3. Market Revenue and Forecast, by Application (2021-2034)
13.3.4. Market Revenue and Forecast, by Administration (2021-2034)
13.3.5. Market Revenue and Forecast, by Distribution Channel (2021-2034)
13.3.6. India
13.3.6.1. Market Revenue and Forecast, by Product Type (2021-2034)
13.3.6.2. Market Revenue and Forecast, by Molecular Type (2021-2034)
13.3.6.3. Market Revenue and Forecast, by Application (2021-2034)
13.3.6.4. Market Revenue and Forecast, by Administration (2021-2034)
13.3.7. Market Revenue and Forecast, by Distribution Channel (2021-2034)
13.3.8. China
13.3.8.1. Market Revenue and Forecast, by Product Type (2021-2034)
13.3.8.2. Market Revenue and Forecast, by Molecular Type (2021-2034)
13.3.8.3. Market Revenue and Forecast, by Application (2021-2034)
13.3.8.4. Market Revenue and Forecast, by Administration (2021-2034)
13.3.9. Market Revenue and Forecast, by Distribution Channel (2021-2034)
13.3.10. Japan
13.3.10.1. Market Revenue and Forecast, by Product Type (2021-2034)
13.3.10.2. Market Revenue and Forecast, by Molecular Type (2021-2034)
13.3.10.3. Market Revenue and Forecast, by Application (2021-2034)
13.3.10.4. Market Revenue and Forecast, by Administration (2021-2034)
13.3.10.5. Market Revenue and Forecast, by Distribution Channel (2021-2034)
13.3.11. Rest of APAC
13.3.11.1. Market Revenue and Forecast, by Product Type (2021-2034)
13.3.11.2. Market Revenue and Forecast, by Molecular Type (2021-2034)
13.3.11.3. Market Revenue and Forecast, by Application (2021-2034)
13.3.11.4. Market Revenue and Forecast, by Administration (2021-2034)
13.3.11.5. Market Revenue and Forecast, by Distribution Channel (2021-2034)
13.4. MEA
13.4.1. Market Revenue and Forecast, by Product Type (2021-2034)
13.4.2. Market Revenue and Forecast, by Molecular Type (2021-2034)
13.4.3. Market Revenue and Forecast, by Application (2021-2034)
13.4.4. Market Revenue and Forecast, by Administration (2021-2034)
13.4.5. Market Revenue and Forecast, by Distribution Channel (2021-2034)
13.4.6. GCC
13.4.6.1. Market Revenue and Forecast, by Product Type (2021-2034)
13.4.6.2. Market Revenue and Forecast, by Molecular Type (2021-2034)
13.4.6.3. Market Revenue and Forecast, by Application (2021-2034)
13.4.6.4. Market Revenue and Forecast, by Administration (2021-2034)
13.4.7. Market Revenue and Forecast, by Distribution Channel (2021-2034)
13.4.8. North Africa
13.4.8.1. Market Revenue and Forecast, by Product Type (2021-2034)
13.4.8.2. Market Revenue and Forecast, by Molecular Type (2021-2034)
13.4.8.3. Market Revenue and Forecast, by Application (2021-2034)
13.4.8.4. Market Revenue and Forecast, by Administration (2021-2034)
13.4.9. Market Revenue and Forecast, by Distribution Channel (2021-2034)
13.4.10. South Africa
13.4.10.1. Market Revenue and Forecast, by Product Type (2021-2034)
13.4.10.2. Market Revenue and Forecast, by Molecular Type (2021-2034)
13.4.10.3. Market Revenue and Forecast, by Application (2021-2034)
13.4.10.4. Market Revenue and Forecast, by Administration (2021-2034)
13.4.10.5. Market Revenue and Forecast, by Distribution Channel (2021-2034)
13.4.11. Rest of MEA
13.4.11.1. Market Revenue and Forecast, by Product Type (2021-2034)
13.4.11.2. Market Revenue and Forecast, by Molecular Type (2021-2034)
13.4.11.3. Market Revenue and Forecast, by Application (2021-2034)
13.4.11.4. Market Revenue and Forecast, by Administration (2021-2034)
13.4.11.5. Market Revenue and Forecast, by Distribution Channel (2021-2034)
13.5. Latin America
13.5.1. Market Revenue and Forecast, by Product Type (2021-2034)
13.5.2. Market Revenue and Forecast, by Molecular Type (2021-2034)
13.5.3. Market Revenue and Forecast, by Application (2021-2034)
13.5.4. Market Revenue and Forecast, by Administration (2021-2034)
13.5.5. Market Revenue and Forecast, by Distribution Channel (2021-2034)
13.5.6. Brazil
13.5.6.1. Market Revenue and Forecast, by Product Type (2021-2034)
13.5.6.2. Market Revenue and Forecast, by Molecular Type (2021-2034)
13.5.6.3. Market Revenue and Forecast, by Application (2021-2034)
13.5.6.4. Market Revenue and Forecast, by Administration (2021-2034)
13.5.7. Market Revenue and Forecast, by Distribution Channel (2021-2034)
13.5.8. Rest of LATAM
13.5.8.1. Market Revenue and Forecast, by Product Type (2021-2034)
13.5.8.2. Market Revenue and Forecast, by Molecular Type (2021-2034)
13.5.8.3. Market Revenue and Forecast, by Application (2021-2034)
13.5.8.4. Market Revenue and Forecast, by Administration (2021-2034)
13.5.8.5. Market Revenue and Forecast, by Distribution Channel (2021-2034)
Chapter 14. Company Profiles
14.1. DR. Reddys Laboratries Ltd
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. Baxter International
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. Mylan N.A
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. Teva Pharmaceuticals
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. Teva Pharmaceuticals
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. Sanofi S.A
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. Fresenius Kabi
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. Pfizer Inc
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
14.9. Cipla Ltd
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives
14.10. Merck & Co. Inc
14.10.1. Company Overview
14.10.2. Product Offerings
14.10.3. Financial Performance
14.10.4. Recent Initiatives
Chapter 15. Research Methodology
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
Chapter 16. Appendix
16.1. About Us
16.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client